Status:
COMPLETED
Acupuncture for Pain in Sickle Cell Disease
Lead Sponsor:
Deepika Darbari
Conditions:
Sickle Cell Disease
Eligibility:
All Genders
8-22 years
Phase:
NA
Brief Summary
Sickle cell disease (SCD) is the most common genetic disorder in the United States affecting approximately 100,000 individuals primarily of African ancestry. Pain is the most common complication of SC...
Detailed Description
This study will evaluate the acceptability and tolerability of acupuncture in patients with SCD admitted for management of acute pain. SCD patients admitted for pain control will be approached for the...
Eligibility Criteria
Inclusion
- subjects with SCD (HbSS, HbSC, HbSβ0 thalassemia, HbSOArab)
- Admitted for management of pain at Children's National.
- Ability to provide informed consent/assent
Exclusion
- Inability to give informed consent/assent as determined by the investigators
- SCD related complications such as acute chest syndrome requiring supplemental oxygen, fever with bacteremia or concern for serious infection ex. osteomyelitis Local -skin infection or condition not feasible for acupuncture
- Pregnancy or lactation
Key Trial Info
Start Date :
October 23 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 13 2022
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT04122378
Start Date
October 23 2018
End Date
October 13 2022
Last Update
December 4 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's National Health System
Washington D.C., District of Columbia, United States, 20010